Floatz logo

Vedolizumab

Biphenotypic Acute Leukemia

Federal Research Institute of Pediatric Hematology, Oncology and Immunologymonoclonal_antibodyPhase 3Active
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
81/ 100

Competitive context

42 Active assets in the Biphenotypic Acute Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2/3BB
Cytosin-Arabinosid
University of Washington
Phase 2BB
FILGRASTIM
Ossium Health, Inc.
Phase 2BB
Busulphan
Ossium Health, Inc.
Phase 2BB
Thiotepa
Fred Hutchinson Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

Vedolizumab is also rated in:

lymphomaDormant
B
Indicative ·
59 / 100
View asset →
colitisDormant
B
Indicative ·
58 / 100
View asset →
inflammatory bowel diseaseDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →